Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 186

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

RNA-dependent RNA targeting by CRISPR-Cas9

Strutt, Steven C, Torrez, Rachel M, Kaya, Emine, Negrete, Oscar A, Doudna, Jennifer A·2018·eLife

Abstract

Double-stranded DNA (dsDNA) binding and cleavage by Cas9 is a hallmark of type II CRISPR-Cas bacterial adaptive immunity. All known Cas9 enzymes are thought to recognize DNA exclusively as a natural substrate, providing protection against DNA phage and plasmids. Here, we show that Cas9 enzymes from both subtypes II-A and II-C can recognize and cleave single-stranded RNA (ssRNA) by an RNA-guided mechanism that is independent of a protospacer-adjacent motif (PAM) sequence in the target RNA. RNA-guided RNA cleavage is programmable and site-specific, and we find that this activity can be exploited to reduce infection by single-stranded RNA phage in vivo. We also demonstrate that Cas9 can direct PAM-independent repression of gene expression in bacteria. These results indicate that a subset of Cas9 enzymes have the ability to act on both DNA and RNA target sequences, and suggest the potential for use in programmable RNA targeting applications.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.7554/elife.32724

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. SauCas9 cleaves single-stranded RNA without a PAMmer. (A) Schematic of Cas9 proteins tested for sgRNA-mediated RNA cleavage. RuvC, RuvC nuclease domain; BH, bridge-helix; REC, recognition domain; HNH, HNH nuclease domain; PLL, phosphate-lock loop; WED, wedge domain; PI, PAM-interacting domain. Adapted from (Nishimasu et al., 2014; 2015; Hirano et al., 2016; Yamada et al., 2017). (B) Representative in vitro cleavage of ssRNA by Cas9-sgRNA RNP complexes of homologs in (A). Radiolabeled pUC target RNA was incubated with Cas9 RNP at 37˚C and time points were taken at 0, 10, 30, and 60 min. Full time course is presented in Figure 1—figure supplement 1B. T1 indicates size markers generated by RNase T1 digestion of ssRNA target. Size in nucleotides is indicated on the left. (C) (Right) In vitro cleavage assay of various RNA substrates (Left). Full time course is presented in Figure 1—figure supplement 3A.
Figure 1. SauCas9 cleaves single-stranded RNA without a PAMmer. (A) Schematic of Cas9 proteins tested for sgRNA-mediated RNA cleavage. RuvC, RuvC nuclease domain; BH, bridge-helix; REC, recognition domain; HNH, HNH nuclease domain; PLL, phosphate-lock loop; WED, wedge domain; PI, PAM-interacting domain. Adapted from (Nishimasu et al., 2014; 2015; Hirano et al., 2016; Yamada et al., 2017). (B) Representative in vitro cleavage of ssRNA by Cas9-sgRNA RNP complexes of homologs in (A). Radiolabeled pUC target RNA was incubated with Cas9 RNP at 37˚C and time points were taken at 0, 10, 30, and 60 min. Full time course is presented in Figure 1—figure supplement 1B. T1 indicates size markers generated by RNase T1 digestion of ssRNA target. Size in nucleotides is indicated on the left. (C) (Right) In vitro cleavage assay of various RNA substrates (Left). Full time course is presented in Figure 1—figure supplement 3A.CC BY · PubMed Central
Figure 1—figure supplement 1. RNA is cleaved by SauCas9 and CjeCas9. (A) Phylogenetic tree of Cas9 homologs assayed for ssRNA cleavage activity. Tree was generated using homologs gathered from (Chylinski et al., 2014). Only homologs tested for activity are highlighted as leaves on the tree. Clades are colored by Cas9 sub-type. (B) Representative in vitro cleavage gel for ssRNA targeting by various Cas9 homologs in (A). Target used for cleavage was the pUC ssRNA. Time points are 0, 1, 2, 5, 10, 30, 60, and 120 min. T1 RNase digest size fragments are given on the left. (C) Quantification of fraction cleaved in (B). Fit was determined in Prism using a single-exponential decay model. Error bars represent the mean ± S.D. (n = 3). (D) Apparent pseudo-first order fit parameters of the data in (C) where ‘% cleaved’ indicates the fraction of substrate cleaved when the reaction plateaus (mean ± S.D.).
Figure 1—figure supplement 1. RNA is cleaved by SauCas9 and CjeCas9. (A) Phylogenetic tree of Cas9 homologs assayed for ssRNA cleavage activity. Tree was generated using homologs gathered from (Chylinski et al., 2014). Only homologs tested for activity are highlighted as leaves on the tree. Clades are colored by Cas9 sub-type. (B) Representative in vitro cleavage gel for ssRNA targeting by various Cas9 homologs in (A). Target used for cleavage was the pUC ssRNA. Time points are 0, 1, 2, 5, 10, 30, 60, and 120 min. T1 RNase digest size fragments are given on the left. (C) Quantification of fraction cleaved in (B). Fit was determined in Prism using a single-exponential decay model. Error bars represent the mean ± S.D. (n = 3). (D) Apparent pseudo-first order fit parameters of the data in (C) where ‘% cleaved’ indicates the fraction of substrate cleaved when the reaction plateaus (mean ± S.D.).CC BY · PubMed Central
Figure 1—figure supplement 2. ssRNA cleavage is similar to canonical dsDNA cleavage by Cas9. (A) In vitro SauCas9 cleavage assay of ssRNA. Reactions were incubated with wild-type (Wt SauCas9) or catalytically-inactive dSauCas9 (D10A and N580A) in the presence or absence of sgRNA as indicated above the reactions. EDTA was included at 25 mM where applicable. (B) SauCas9 ssRNA cleavage is single-turnover. SauCas9 RNP was incubated with the RNA target in the various ratios indicated. (A and B) Time points are 0, 1, 2, 5, 10, 30, 60, and 120 min. T1 RNase digest size fragments are given on the left. Target used for cleavage was the pUC ssRNA. (C) Graphical representation of ssRNA fraction cleaved of reactions in (B). Fit was determined in Prism using a single-exponential decay model. Error bars represent the mean ± S.D. (n = 3). (D) Mapping of SauCas9 ssRNA cleavage site. Reaction products from a 2 hr incubation of SauCas9 RNP with the pUC ssRNA target were separated on a 15% denaturing PAGE gel with a hydrolysis and T1 digest ladder to determine exact site of the major cleavage product. (E) Diagram of canonical DNA cleavage position and ssRNA cleavage position as determined in (D).
Figure 1—figure supplement 2. ssRNA cleavage is similar to canonical dsDNA cleavage by Cas9. (A) In vitro SauCas9 cleavage assay of ssRNA. Reactions were incubated with wild-type (Wt SauCas9) or catalytically-inactive dSauCas9 (D10A and N580A) in the presence or absence of sgRNA as indicated above the reactions. EDTA was included at 25 mM where applicable. (B) SauCas9 ssRNA cleavage is single-turnover. SauCas9 RNP was incubated with the RNA target in the various ratios indicated. (A and B) Time points are 0, 1, 2, 5, 10, 30, 60, and 120 min. T1 RNase digest size fragments are given on the left. Target used for cleavage was the pUC ssRNA. (C) Graphical representation of ssRNA fraction cleaved of reactions in (B). Fit was determined in Prism using a single-exponential decay model. Error bars represent the mean ± S.D. (n = 3). (D) Mapping of SauCas9 ssRNA cleavage site. Reaction products from a 2 hr incubation of SauCas9 RNP with the pUC ssRNA target were separated on a 15% denaturing PAGE gel with a hydrolysis and T1 digest ladder to determine exact site of the major cleavage product. (E) Diagram of canonical DNA cleavage position and ssRNA cleavage position as determined in (D).CC BY · PubMed Central
Figure 1—figure supplement 3. SauCas9 cleavage of different nucleic acid substrates. (A) Representative cleavage assay of nucleic acid substrates diagramed in (B) by SauCas9. Asterisk denotes an off-target cleavage site. Time points are 0, 1, 2, 5, 10, 30, 60, and 120 min. T1 RNase digest size fragments are given on the left. (C) Quantification of results in (A). Fit was determined in Prism using a single-exponential decay model. Error bars represent the mean ± S.D. (n = 3). Apparent pseudo-first order rate constant (kcleave ± S.D.) is given to the right of the substrate legend. N.D. indicates that an accurate rate cannot be determined due to the reaction reaching completion before the second time point. N.s., not significant.
Figure 1—figure supplement 3. SauCas9 cleavage of different nucleic acid substrates. (A) Representative cleavage assay of nucleic acid substrates diagramed in (B) by SauCas9. Asterisk denotes an off-target cleavage site. Time points are 0, 1, 2, 5, 10, 30, 60, and 120 min. T1 RNase digest size fragments are given on the left. (C) Quantification of results in (A). Fit was determined in Prism using a single-exponential decay model. Error bars represent the mean ± S.D. (n = 3). Apparent pseudo-first order rate constant (kcleave ± S.D.) is given to the right of the substrate legend. N.D. indicates that an accurate rate cannot be determined due to the reaction reaching completion before the second time point. N.s., not significant.CC BY · PubMed Central
Figure 1—figure supplement 4. SauCas9 prefers a complementary region of 23nt for binding and cleavage. (A) Diagram of pUC ssRNA target and regions of complementary for the different length sgRNAs. (B) Representative in vitro cleavage assays using sgRNAs with a complementary region to the target of the indicated lengths. Time points are 0, 1, 2, 5, 10, 30, 60, and 120 min. T1 RNase digest size fragments are given on the left. (C) Quantification of cleavage products from reactions in (B). Length of targeting region of the sgRNA given as n-mer. Fit was determined in Prism using a single-exponential decay model. Error bars represent the mean ± S.D. (n = 3). (D) Filter binding data for dSauCas9 and the structured RNA substrates were fit in Prism using a one-site binding model and the apparent dissociation constant (Kd,app) was determined. Bars represent the mean ± S.D. (n = 3).
Figure 1—figure supplement 4. SauCas9 prefers a complementary region of 23nt for binding and cleavage. (A) Diagram of pUC ssRNA target and regions of complementary for the different length sgRNAs. (B) Representative in vitro cleavage assays using sgRNAs with a complementary region to the target of the indicated lengths. Time points are 0, 1, 2, 5, 10, 30, 60, and 120 min. T1 RNase digest size fragments are given on the left. (C) Quantification of cleavage products from reactions in (B). Length of targeting region of the sgRNA given as n-mer. Fit was determined in Prism using a single-exponential decay model. Error bars represent the mean ± S.D. (n = 3). (D) Filter binding data for dSauCas9 and the structured RNA substrates were fit in Prism using a one-site binding model and the apparent dissociation constant (Kd,app) was determined. Bars represent the mean ± S.D. (n = 3).CC BY · PubMed Central
Figure 2. In vitro RNA cleavage is impaired by strong secondary structure. (A) Schematic representation of structured RNA targets for in vitro cleavage assays. Symbols on right indicate relative level of cleavage activity for each substrate: ‘-”, no cleavage; ‘+”, low cleavage; ‘++”, medium cleavage; ‘+++” high cleavage. (B) Representative cleavage assay of partially-duplexed RNA targets diagrammed in (A). T1 indicates size markers generated by RNase T1 digestion of ssRNA target. Size in nucleotides is indicated on the left. (C and D) Fraction of target cleaved (C) and Kd,app (D) for substrates diagrammed in (A). Fits were determined in Prism using a single-exponential decay and a one-site binding model, respectively. Bars represent mean ± S.D. (n = 3). N.s. denotes no significant cleavage or binding.
Figure 2. In vitro RNA cleavage is impaired by strong secondary structure. (A) Schematic representation of structured RNA targets for in vitro cleavage assays. Symbols on right indicate relative level of cleavage activity for each substrate: ‘-”, no cleavage; ‘+”, low cleavage; ‘++”, medium cleavage; ‘+++” high cleavage. (B) Representative cleavage assay of partially-duplexed RNA targets diagrammed in (A). T1 indicates size markers generated by RNase T1 digestion of ssRNA target. Size in nucleotides is indicated on the left. (C and D) Fraction of target cleaved (C) and Kd,app (D) for substrates diagrammed in (A). Fits were determined in Prism using a single-exponential decay and a one-site binding model, respectively. Bars represent mean ± S.D. (n = 3). N.s. denotes no significant cleavage or binding.CC BY · PubMed Central
Figure 2—figure supplement 1. RNA cleavage is limited by the RNA target. (A) Predicted secondary structure of target RNA used in this study. (B) In vitro cleavage assay of ssRNA with SauCas9 was conducted for 2 hr (time points: 0, 1, 2, 5, 10, 30, 60, 120 min). The reaction was split and SauCas9-sgRNA RNP or apo SauCas9 were added. The reaction was further incubated at 37˚C and additional time points at were taken to check for additional cleavage of the target. Time points were taken at 0, 1, 2, 5, 10, 30, 60, and 120 min post-RNP/apo SauCas9 addition. (C) Fit for data in (B) was determined in Prism using a single-exponential decay model. Error bars represent the mean ± S.D. (n = 3). (D) In vitro cleavage assay of two ssRNA targets added sequentially. After 60 min incubation of SauCas9 with the pUC target, another target containing either the same recognition sequence (ON target – reaction 1) or an unrelated sequence (OFF target – reaction 2) were added to the reaction. Cleavage was assayed for an additional 60 min (time points: 0, 10, 30, 60 min). Reactions containing only the second target (Reactions 3 and 4) were conducted with SauCas9 RNP that was incubated for 60 min at 37˚C prior to addition to the cleavage reaction. (E) Quantification of cleavage of second target in (D) for time points after addition. Fit was determined in Prism using a single-exponential decay model. Error bars represent the mean ± S.D. (n = 3).
Figure 2—figure supplement 1. RNA cleavage is limited by the RNA target. (A) Predicted secondary structure of target RNA used in this study. (B) In vitro cleavage assay of ssRNA with SauCas9 was conducted for 2 hr (time points: 0, 1, 2, 5, 10, 30, 60, 120 min). The reaction was split and SauCas9-sgRNA RNP or apo SauCas9 were added. The reaction was further incubated at 37˚C and additional time points at were taken to check for additional cleavage of the target. Time points were taken at 0, 1, 2, 5, 10, 30, 60, and 120 min post-RNP/apo SauCas9 addition. (C) Fit for data in (B) was determined in Prism using a single-exponential decay model. Error bars represent the mean ± S.D. (n = 3). (D) In vitro cleavage assay of two ssRNA targets added sequentially. After 60 min incubation of SauCas9 with the pUC target, another target containing either the same recognition sequence (ON target – reaction 1) or an unrelated sequence (OFF target – reaction 2) were added to the reaction. Cleavage was assayed for an additional 60 min (time points: 0, 10, 30, 60 min). Reactions containing only the second target (Reactions 3 and 4) were conducted with SauCas9 RNP that was incubated for 60 min at 37˚C prior to addition to the cleavage reaction. (E) Quantification of cleavage of second target in (D) for time points after addition. Fit was determined in Prism using a single-exponential decay model. Error bars represent the mean ± S.D. (n = 3).CC BY · PubMed Central
Figure 3. SauCas9 confers in vivo protection against an RNA phage. (A) Overview of MS2 targeting screen. Guides tiled against the library were cloned into sgRNA expression plasmids and co-transformed into E. coli with a plasmid containing wild-type SauCas9 under inducible control. Plasmids from surviving colonies after MS2 selection were recovered and sequenced. For more detail, see Materials and methods. (B) Number of guides with significant positive enrichment from three biological experiments. SNP, guides with single-nucleotide mismatch. (C) Box and whiskers plot of average log2 fold-change of perfect MS2 guides by length. Whiskers represent 5% and 95% values with outliers graphed as points. *p<0.05, **p<0.01, ****p<0.0001, by one-way ANOVA. (D) (Upper) Log2 fold-change of guides with an FDR-corrected p-value<0.05 mapped to the MS2 genome for MOI-100 treatment. Schematic of MS2 genome is provided above. (Lower) Individual guides mapped to highlighted regions of MS2 genome. Other graphs for MOI-10 and −100 treatments are presented in Figure 3—figure supplement 1. (E) Representative plaque assay of SauCas9 in vivo protection. E. coli containing constructs on the right are spotted with various phage dilutions as indicated. Scr signifies that the targeting portion of the guide has been scrambled to serve as a non-targeting control. (F) Relative plaque forming units (PFU) (mean ± S.D., n = 3) from results in (E). More guides and controls are presented in Figure 3—figure supplement 3.
Figure 3. SauCas9 confers in vivo protection against an RNA phage. (A) Overview of MS2 targeting screen. Guides tiled against the library were cloned into sgRNA expression plasmids and co-transformed into E. coli with a plasmid containing wild-type SauCas9 under inducible control. Plasmids from surviving colonies after MS2 selection were recovered and sequenced. For more detail, see Materials and methods. (B) Number of guides with significant positive enrichment from three biological experiments. SNP, guides with single-nucleotide mismatch. (C) Box and whiskers plot of average log2 fold-change of perfect MS2 guides by length. Whiskers represent 5% and 95% values with outliers graphed as points. *p<0.05, **p<0.01, ****p<0.0001, by one-way ANOVA. (D) (Upper) Log2 fold-change of guides with an FDR-corrected p-value<0.05 mapped to the MS2 genome for MOI-100 treatment. Schematic of MS2 genome is provided above. (Lower) Individual guides mapped to highlighted regions of MS2 genome. Other graphs for MOI-10 and −100 treatments are presented in Figure 3—figure supplement 1. (E) Representative plaque assay of SauCas9 in vivo protection. E. coli containing constructs on the right are spotted with various phage dilutions as indicated. Scr signifies that the targeting portion of the guide has been scrambled to serve as a non-targeting control. (F) Relative plaque forming units (PFU) (mean ± S.D., n = 3) from results in (E). More guides and controls are presented in Figure 3—figure supplement 3.CC BY · PubMed Central
Figure 3—figure supplement 1. Enriched guides do not display sequence bias and cluster to regions on the MS2 genome. (A) (Left) Stacked bar graph of positively enriched guides (FDR-adjusted p-value<0.05) for perfectly complementary and single-nucleotide mismatch (SNP) guides for a multiplicities of infection (MOI) of 10 and 100. (Right) Percentages of perfect and SNP guides by length averaged across the control libraries (n = 3). (B) WebLogo (Crooks et al., 2004) representation of positively enriched guides (perfect complementarity, FDR-adjusted p-value<0.05) for MOI-10 (n = 84) and MOI-100 (n = 107). Different length guides were aligned at their 3´ end, which contains the pre-ordered ‘seed’ region (Jiang et al., 2015). (C) (Upper) Log2 fold-change of positively enriched guides (FDR-adjusted p-value<0.05) mapped to the MS2 genome for MOI-100 treatment. Schematic of MS2 genome is provided above. (Lower) Individual guides mapped to highlighted regions of MS2 genome. (D) Log2 fold-change of guides with an FDR-adjusted p-value<0.05 mapped to the MS2 genome for MOI-10 treatment.
Figure 3—figure supplement 1. Enriched guides do not display sequence bias and cluster to regions on the MS2 genome. (A) (Left) Stacked bar graph of positively enriched guides (FDR-adjusted p-value<0.05) for perfectly complementary and single-nucleotide mismatch (SNP) guides for a multiplicities of infection (MOI) of 10 and 100. (Right) Percentages of perfect and SNP guides by length averaged across the control libraries (n = 3). (B) WebLogo (Crooks et al., 2004) representation of positively enriched guides (perfect complementarity, FDR-adjusted p-value<0.05) for MOI-10 (n = 84) and MOI-100 (n = 107). Different length guides were aligned at their 3´ end, which contains the pre-ordered ‘seed’ region (Jiang et al., 2015). (C) (Upper) Log2 fold-change of positively enriched guides (FDR-adjusted p-value<0.05) mapped to the MS2 genome for MOI-100 treatment. Schematic of MS2 genome is provided above. (Lower) Individual guides mapped to highlighted regions of MS2 genome. (D) Log2 fold-change of guides with an FDR-adjusted p-value<0.05 mapped to the MS2 genome for MOI-10 treatment.CC BY · PubMed Central
Figure 3—figure supplement 2. Enriched MS2 targeting guides mapped to MS2 genome structure. Structure of the MS2 genome inside the viral particle was obtained from a recently published EM structure (Dai et al., 2017) and guides (red) significantly enriched in the MOI-100 treatment (FDR-adjusted p-value<0.05) were mapped to the MS2 genome and subsequently visualized in Forna (Kerpedjiev et al., 2015).
Figure 3—figure supplement 2. Enriched MS2 targeting guides mapped to MS2 genome structure. Structure of the MS2 genome inside the viral particle was obtained from a recently published EM structure (Dai et al., 2017) and guides (red) significantly enriched in the MOI-100 treatment (FDR-adjusted p-value<0.05) were mapped to the MS2 genome and subsequently visualized in Forna (Kerpedjiev et al., 2015).CC BY · PubMed Central
Figure 3—figure supplement 3. Confirmation that enriched guides from the MS2 screen confer protection against MS2 infection. (A) Representative plaque assay for lawns of E. coli expressing wtSauCas9 and sgRNA of different length spotted with phage dilutions indicated. Here, the sgRNA with the highest fold-change in both MOI-10 and −100 samples was chosen for each length. The 23-mer sgRNA produces hazy plaques for an unknown reason. All other guides tested, including a different 23-mer sgRNA, produced clear plaques. (B) Quantification of relative plaque forming units (PFU, mean ± S.D., n = 3) from data in (A). (C) Same as in (A). Guides were two ‘control’ guides that were significantly enriched in both MOI-10 and −100 treatments during phage selection. Scrambled (scr) indicates random shuffling of the target sequence to serve as a non-targeting control. Scrambled sequences were verified against the MS2 genome and its reverse-complement to ensure no partial matches. (D) Quantification of relative PFU as in (C). Guides 14238 and 14210 confer ~10 fold protection over their scrambled counterparts. The level of protection is similar to perfectly complementary guides (B, and see Figure 3E and F). (E) Predicted binding of guide 14238 (green) to a fragment of the MS2 genome (red, nts: 1533–1563) using RNAhybrid (Rehmsmeier et al., 2004).
Figure 3—figure supplement 3. Confirmation that enriched guides from the MS2 screen confer protection against MS2 infection. (A) Representative plaque assay for lawns of E. coli expressing wtSauCas9 and sgRNA of different length spotted with phage dilutions indicated. Here, the sgRNA with the highest fold-change in both MOI-10 and −100 samples was chosen for each length. The 23-mer sgRNA produces hazy plaques for an unknown reason. All other guides tested, including a different 23-mer sgRNA, produced clear plaques. (B) Quantification of relative plaque forming units (PFU, mean ± S.D., n = 3) from data in (A). (C) Same as in (A). Guides were two ‘control’ guides that were significantly enriched in both MOI-10 and −100 treatments during phage selection. Scrambled (scr) indicates random shuffling of the target sequence to serve as a non-targeting control. Scrambled sequences were verified against the MS2 genome and its reverse-complement to ensure no partial matches. (D) Quantification of relative PFU as in (C). Guides 14238 and 14210 confer ~10 fold protection over their scrambled counterparts. The level of protection is similar to perfectly complementary guides (B, and see Figure 3E and F). (E) Predicted binding of guide 14238 (green) to a fragment of the MS2 genome (red, nts: 1533–1563) using RNAhybrid (Rehmsmeier et al., 2004).CC BY · PubMed Central
Figure 3—figure supplement 4. Effect of single-nucleotide mismatches on ssRNA targeting. (A–B) Heatmap of average log2 fold-change for all single-nucleotide mismatch (SNP) guides in MOI-10 (A) and MOI-100 (B) treatment. Deeper blue represents greater negative selection of guides indicating greater sensitivity to mismatches at that position. While deeper black represents greater positive selection indicating that mismatches at that position are more tolerated. Positions are given as distance from 3´ end of the targeting region of the sgRNA. (C) Diagram of target ssRNAs with SNPs for in vitro cleavage assays. Red highlights the region complementary to the guide while black nucleotides indicate the mismatched base in the targeting region. Numbering of nucleotides is labeled from 1 to 23 to reflect positions in (A) and (B). (D) Quantification of in vitro cleavage assays with mismatched targets in (C). Bars represent the mean ± S.D. (n = 3). ‘Wt’ indicates 23nt of perfect complementarity between the sgRNA and the target.
Figure 3—figure supplement 4. Effect of single-nucleotide mismatches on ssRNA targeting. (A–B) Heatmap of average log2 fold-change for all single-nucleotide mismatch (SNP) guides in MOI-10 (A) and MOI-100 (B) treatment. Deeper blue represents greater negative selection of guides indicating greater sensitivity to mismatches at that position. While deeper black represents greater positive selection indicating that mismatches at that position are more tolerated. Positions are given as distance from 3´ end of the targeting region of the sgRNA. (C) Diagram of target ssRNAs with SNPs for in vitro cleavage assays. Red highlights the region complementary to the guide while black nucleotides indicate the mismatched base in the targeting region. Numbering of nucleotides is labeled from 1 to 23 to reflect positions in (A) and (B). (D) Quantification of in vitro cleavage assays with mismatched targets in (C). Bars represent the mean ± S.D. (n = 3). ‘Wt’ indicates 23nt of perfect complementarity between the sgRNA and the target.CC BY · PubMed Central
Figure 4. SauCas9 repression of a GFP reporter in vivo. (A) Comparison of dSpy and dSauCas9 to repress GFP expression on the DNA and RNA level. GFP signal is normalized to OD600 to control for difference in cell density between samples. GFP/OD600 ratios for guide alone and RNP are normalized to values for a non-targeting guide vector and an Apo protein control, respectively. Target sites were chosen to be adjacent to PAM sites for Spy, Sau, both, or neither as indicated. Note: the slight GFP repression observed with dSpyCas9 using the target sequence adjacent to the Sau PAM (CAGAGT) likely results from the ability of SpyCas9 to use an NAG PAM, albeit with reduced efficiency (Hsu et al., 2013). ****p<0.0001 by one-way ANOVA. (B) Relative expression of GFP using guides with different length targeting sequences. Target site here is the GFP2 sequence chosen for its robust targeting activity. (C) (Upper) Diagram of targeting sequences across the GFP mRNA and ribosome-binding site (RBS). (Lower) Relative expression of GFP of SauCas9 RNP normalized to sgRNA alone for targeting sequences across the GFP reporter. Dashed red line indicates that the sgRNA alone is as efficient as the RNP for GFP repression. (A–C) Bars represent mean ± S.D. (n = 3). (D) Model for observed SauCas9 ssRNA targeting activity. We propose that accessible RNA is cleaved or repressed efficiently while structured and protein-bound RNA is not targeted by SauCas9.
Figure 4. SauCas9 repression of a GFP reporter in vivo. (A) Comparison of dSpy and dSauCas9 to repress GFP expression on the DNA and RNA level. GFP signal is normalized to OD600 to control for difference in cell density between samples. GFP/OD600 ratios for guide alone and RNP are normalized to values for a non-targeting guide vector and an Apo protein control, respectively. Target sites were chosen to be adjacent to PAM sites for Spy, Sau, both, or neither as indicated. Note: the slight GFP repression observed with dSpyCas9 using the target sequence adjacent to the Sau PAM (CAGAGT) likely results from the ability of SpyCas9 to use an NAG PAM, albeit with reduced efficiency (Hsu et al., 2013). ****p<0.0001 by one-way ANOVA. (B) Relative expression of GFP using guides with different length targeting sequences. Target site here is the GFP2 sequence chosen for its robust targeting activity. (C) (Upper) Diagram of targeting sequences across the GFP mRNA and ribosome-binding site (RBS). (Lower) Relative expression of GFP of SauCas9 RNP normalized to sgRNA alone for targeting sequences across the GFP reporter. Dashed red line indicates that the sgRNA alone is as efficient as the RNP for GFP repression. (A–C) Bars represent mean ± S.D. (n = 3). (D) Model for observed SauCas9 ssRNA targeting activity. We propose that accessible RNA is cleaved or repressed efficiently while structured and protein-bound RNA is not targeted by SauCas9.CC BY · PubMed Central
Figure 4—figure supplement 1. Repression of GFP mRNA. (A) dSauCas9-sgRNA directed against a GFP mRNA (coding) or antisense (noncoding) sequence. GFP2 and GFP6 refer to guides diagrammed in Figure 4C. Dashed red line indicates that the sgRNA alone is as efficient as the SauCas9 RNP for GFP repression. Bars represent mean ± S.D. (n = 3). ***p<0.001, ****p<0.0001, by one-way ANOVA. (B) Electrophoretic mobility shift assay (EMSA) confirming that dSauCas9 does not bind dsDNA adjacent to non-canonical PAMs. Targeting sequence is identical for all substrates but with varied PAM sequences as indicated for the guides in Figure 4C. Final concentrations of dSauCas9 from left to right: 0, 0.1, 0.5, 1, 5, 10, 50, 100 nM. (C) Comparison of ability of dSau and wtSauCas9 to repress GFP expression in vivo. Bars represent mean ± S.D. (n = 3).
Figure 4—figure supplement 1. Repression of GFP mRNA. (A) dSauCas9-sgRNA directed against a GFP mRNA (coding) or antisense (noncoding) sequence. GFP2 and GFP6 refer to guides diagrammed in Figure 4C. Dashed red line indicates that the sgRNA alone is as efficient as the SauCas9 RNP for GFP repression. Bars represent mean ± S.D. (n = 3). ***p<0.001, ****p<0.0001, by one-way ANOVA. (B) Electrophoretic mobility shift assay (EMSA) confirming that dSauCas9 does not bind dsDNA adjacent to non-canonical PAMs. Targeting sequence is identical for all substrates but with varied PAM sequences as indicated for the guides in Figure 4C. Final concentrations of dSauCas9 from left to right: 0, 0.1, 0.5, 1, 5, 10, 50, 100 nM. (C) Comparison of ability of dSau and wtSauCas9 to repress GFP expression in vivo. Bars represent mean ± S.D. (n = 3).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Research works printed but not linked: 48

  1. Abudayyeh, 2016, C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector, Science, 353, aaf5573, 10.1126/science.aaf5573 · DOI · Paper page
  2. Anders, 2014, Structural basis of PAM-dependent target DNA recognition by the Cas9 endonuclease, Nature, 513, 569, 10.1038/nature13579 · DOI · Paper page
  3. Batra, 2017, Elimination of toxic microsatellite repeat expansion RNA by RNA-Targeting Cas9, Cell, 170, 899, 10.1016/j.cell.2017.07.010 · DOI · Paper page
  4. Bercy, 2015, Hairpins under tension: RNA versus DNA, Nucleic Acids Research, 43, gkv860, 10.1093/nar/gkv860 · DOI
  5. Bisaria, 2017, Lessons from enzyme kinetics reveal specificity principles for rna-guided nucleases in RNA interference and CRISPR-based genome editing, Cell Systems, 4, 21, 10.1016/j.cels.2016.12.010 · DOI
  6. Chylinski, 2013, The tracrRNA and Cas9 families of type II CRISPR-Cas immunity systems, RNA Biology, 10, 726, 10.4161/rna.24321 · DOI · Paper page
  7. Cong, 2013, Multiplex genome engineering using CRISPR/Cas systems, Science, 339, 819, 10.1126/science.1231143 · DOI · Paper page
  8. Crooks, 2004, WebLogo: a sequence logo generator, Genome Research, 14, 1188, 10.1101/gr.849004 · DOI · Paper page
  9. Dai, 2017, In situ structures of the genome and genome-delivery apparatus in a single-stranded RNA virus, Nature, 541, 112, 10.1038/nature20589 · DOI · Paper page
  10. Deveau, 2008, Phage response to CRISPR-encoded resistance in Streptococcus thermophilus, Journal of Bacteriology, 190, 1390, 10.1128/JB.01412-07 · DOI · Paper page
  11. East-Seletsky, 2016, Two distinct RNase activities of CRISPR-C2c2 enable guide-RNA processing and RNA detection, Nature, 538, 270, 10.1038/nature19802 · DOI · Paper page
  12. Friedland, 2015, Characterization of Staphylococcus aureus Cas9: a smaller Cas9 for all-in-one adeno-associated virus delivery and paired nickase applications, Genome Biology, 16, 257, 10.1186/s13059-015-0817-8 · DOI · Paper page
  13. Fu, 2016, Distinct patterns of Cas9 mismatch tolerance in vitro and in vivo, Nucleic Acids Research, 44, 5365, 10.1093/nar/gkw417 · DOI
  14. Garneau, 2010, The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA, Nature, 468, 67, 10.1038/nature09523 · DOI · Paper page
  15. Gasiunas, 2012, Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria, PNAS, 109, E2579, 10.1073/pnas.1208507109 · DOI · Paper page
  16. Gorski, 2017, RNA-based recognition and targeting: sowing the seeds of specificity, Nature Reviews Molecular Cell Biology, 18, 215, 10.1038/nrm.2016.174 · DOI · Paper page
  17. Hirano, 2016, Structure and engineering of francisella novicida Cas9, Cell, 164, 950, 10.1016/j.cell.2016.01.039 · DOI · Paper page
  18. Jiang, 2015, STRUCTURAL BIOLOGY. A Cas9-guide RNA complex preorganized for target DNA recognition, Science, 348, 1477, 10.1126/science.aab1452 · DOI · Paper page
  19. Jinek, 2012, A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity, Science, 337, 816, 10.1126/science.1225829 · DOI · Paper page
  20. Kerpedjiev, 2015, Forna (force-directed RNA): Simple and effective online RNA secondary structure diagrams, Bioinformatics, 31, 3377, 10.1093/bioinformatics/btv372 · DOI · Paper page
  21. Kleinstiver, 2015, Broadening the targeting range of Staphylococcus aureus CRISPR-Cas9 by modifying PAM recognition, Nature Biotechnology, 33, 1293, 10.1038/nbt.3404 · DOI · Paper page
  22. Kou, 2016, Benefits and Challenges with Applying Unique Molecular Identifiers in Next Generation Sequencing to Detect Low Frequency Mutations, PLoS One, 11, e0146638, 10.1371/journal.pone.0146638 · DOI
  23. Langmead, 2012, Fast gapped-read alignment with Bowtie 2, Nature Methods, 9, 357, 10.1038/nmeth.1923 · DOI · Paper page
  24. Liu, 2016, Targeting cellular mRNAs translation by CRISPR-Cas9, Scientific Reports, 6, srep29652, 10.1038/srep29652 · DOI
  25. Loughrey, 2014, SHAPE-Seq 2.0: systematic optimization and extension of high-throughput chemical probing of RNA secondary structure with next generation sequencing, Nucleic Acids Research, 42, e165, 10.1093/nar/gku909 · DOI
  26. Ma, 2015, Single-Stranded DNA cleavage by divergent CRISPR-Cas9 Enzymes, Molecular Cell, 60, 398, 10.1016/j.molcel.2015.10.030 · DOI
  27. McCarthy, 2012, Differential expression analysis of multifactor RNA-Seq experiments with respect to biological variation, Nucleic Acids Research, 40, 4288, 10.1093/nar/gks042 · DOI · Paper page
  28. Mohanraju, 2016, Diverse evolutionary roots and mechanistic variations of the CRISPR-Cas systems, Science, 353, aad5147, 10.1126/science.aad5147 · DOI · Paper page
  29. Nelles, 2015, Applications of Cas9 as an RNA-programmed RNA-binding protein, BioEssays, 37, 732, 10.1002/bies.201500001 · DOI
  30. Nelles, 2016, Programmable RNA tracking in live cells with CRISPR/Cas9, Cell, 165, 488, 10.1016/j.cell.2016.02.054 · DOI · Paper page
  31. Nishimasu, 2015, Crystal structure of Staphylococcus aureus Cas9, Cell, 162, 1113, 10.1016/j.cell.2015.08.007 · DOI · Paper page
  32. O'Connell, 2014, Programmable RNA recognition and cleavage by CRISPR/Cas9, Nature, 516, 263, 10.1038/nature13769 · DOI · Paper page
  33. Oakes, 2016, Profiling of engineering hotspots identifies an allosteric CRISPR-Cas9 switch, Nature Biotechnology, 34, 646, 10.1038/nbt.3528 · DOI · Paper page
  34. Pei, 2008, PROMALS3D: a tool for multiple protein sequence and structure alignments, Nucleic Acids Research, 36, 2295, 10.1093/nar/gkn072 · DOI · Paper page
  35. Phanstiel, 2014, Sushi.R: flexible, quantitative and integrative genomic visualizations for publication-quality multi-panel figures, Bioinformatics, 30, 2808, 10.1093/bioinformatics/btu379 · DOI · Paper page
  36. Rehmsmeier, 2004, Fast and effective prediction of microRNA/target duplexes, RNA, 10, 1507, 10.1261/rna.5248604 · DOI · Paper page
  37. Rio, 2012, Filter-binding assay for analysis of RNA-protein interactions, Cold Spring Harbor Protocols, 2012, pdb.prot071449, 10.1101/pdb.prot071449 · DOI
  38. Robinson, 2010, edgeR: a bioconductor package for differential expression analysis of digital gene expression data, Bioinformatics, 26, 139, 10.1093/bioinformatics/btp616 · DOI · Paper page
  39. Sampson, 2013, A CRISPR/Cas system mediates bacterial innate immune evasion and virulence, Nature, 497, 254, 10.1038/nature12048 · DOI · Paper page
  40. Shmakov, 2015, Discovery and functional characterization of diverse class 2 CRISPR-Cas systems, Molecular Cell, 60, 385, 10.1016/j.molcel.2015.10.008 · DOI · Paper page
  41. Smargon, 2017, Cas13b Is a Type VI-B CRISPR-Associated RNA-Guided RNase differentially regulated by accessory proteins Csx27 and Csx28, Molecular Cell, 65, 618, 10.1016/j.molcel.2016.12.023 · DOI · Paper page
  42. Smith, 2017, UMI-tools: modeling sequencing errors in Unique Molecular Identifiers to improve quantification accuracy, Genome Research, 27, 491, 10.1101/gr.209601.116 · DOI · Paper page
  43. Sternberg, 2012, Mechanism of substrate selection by a highly specific CRISPR endoribonuclease, RNA, 18, 661, 10.1261/rna.030882.111 · DOI
  44. Sternberg, 2014, DNA interrogation by the CRISPR RNA-guided endonuclease Cas9, Nature, 507, 62, 10.1038/nature13011 · DOI · Paper page
  45. Szczelkun, 2014, Direct observation of R-loop formation by single RNA-guided Cas9 and Cascade effector complexes, PNAS, 111, 9798, 10.1073/pnas.1402597111 · DOI · Paper page
  46. Wright, 2016, Biology and applications of CRISPR systems: harnessing nature's toolbox for genome engineering, Cell, 164, 29, 10.1016/j.cell.2015.12.035 · DOI · Paper page
  47. Yamada, 2017, Crystal structure of the minimal cas9 from campylobacter jejuni reveals the molecular diversity in the CRISPR-Cas9 systems, Molecular Cell, 65, 1109, 10.1016/j.molcel.2017.02.007 · DOI · Paper page
  48. Zhang, 2015, DNase H activity of neisseria meningitidis Cas9, Molecular Cell, 60, 242, 10.1016/j.molcel.2015.09.020 · DOI

Cited by

See all 186

Metadata

Authors
Strutt, S. C., Torrez, R. M., Kaya, E., Negrete, O. A., & Doudna, J. A.
Affiliations
  • Department of Molecular and Cell Biology, University of California, Berkeley, United States
  • Sandia National Laboratories, Biotechnology and Bioengineering Department, Livermore, United States
Venue
eLife
Published
2018-01-05
Volume
7
ISSN
2050-084X
Cited by
186
References
17
Language
en
Funders
  • National Science Foundation (MCB-1244557)
  • Howard Hughes Medical Institute
  • German Academic Exchange Program
  • Laboratory Directed Research and Development (U.S. Department of Energy's National Nuclear Security Administration under contract DE-NA0003525)
  • Paul Allen Frontiers Science Program

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: RNA-dependent RNA targeting by CRISPR-Cas9. https://app.cochat.ai/papers/10.7554/elife.32724
The paper
Strutt, S. C., Torrez, R. M., Kaya, E., Negrete, O. A., & Doudna, J. A. (2018). RNA-dependent RNA targeting by CRISPR-Cas9. eLife. https://doi.org/10.7554/elife.32724

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.